Clinical trial

Dissecting mTOR Pathway Mosaicism in FCDII-Harbouring Epileptic Brain and Peripheral Tissue.

Name
303113_28022022
Description
Focal cortical dysplasia (FCD) is a malformation of brain development, the most common cause of drug-resistant epilepsy and often caused by mutations in mammalian target of rapamycin (mTOR) pathway genes. Patients with FCD develop drug-resistant seizures. This study will look at FCD tissue removed during epilepsy surgery and aims to detect mutations in mTOR pathway genes in brain cells. Secondly, the investigators will establish if evidence of mutations found in brain cells can also be detected as circulating free DNA (cfDNA) in blood. By looking at which genes are made into proteins in individual cells found in epilepsy surgical tissue (single cell expression profiling),the investigators will attempt to identify new genetic targets in FCD. The main outcome will be finding new causes of epilepsy with FCD and the development of new diagnostic and screening tools.
Trial arms
Trial start
2023-04-09
Estimated PCD
2025-04-08
Trial end
2026-04-08
Status
Recruiting
Treatment
Blood and nasal swab sampling
Genetic screening of DNA samples (blood, mucosal swab, brain tissue) from 60-100 patients with histologically confirmed diagnosis of FCDIIA/B identified from Epilepsy Surgery Databases.
Arms:
Patients with histologically confirmed FCDIIA/B undergoing or post Epilepsy Surgery
Other names:
Analysis of Epilepsy Surgical tissue
Size
60
Primary endpoint
somatic mosaicism
2 years
single cell expression profiling
2 years
phosphorylated targets
2 years
Eligibility criteria
Epilepsy in Focal Cortical Dysplasia Type IIA/B Key Inclusion Criteria: 1. Adult and Paediatric Patients (male and female) 2. A histologically proven diagnosis of FCDIIA/B or a suspected diagnosis of FCDIIA/B (on MRI/EEG and PET grounds) awaiting resective Epilepsy surgery. 3. Able to attend appointment/hospital and undergo sampling of serum and nasal swab 4. Informed Consent Available Key Exclusion Criteria: 5. Any acute or chronic conditions that could limit the ability of the patient to participate in the study. 6. Refusal to give informed consent.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}
Updated at
2023-09-26

1 organization

1 product

2 indications

Indication
Epilepsy